Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Atorvastatin for Preventing Contrast-induced Nephropathy
NCT02114346Phase 3Completed
- Start
- Jul 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Atorva in contrast-induced nephropathy (CIN). Started Jul 2013; status: completed.
02
Drugs
Atorva
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT02114346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02114346.